A clinical-stage biotech like early Kite Pharma (now Gilead's Yescarta) or Juno Therapeutics (now BMS's Breyanzi), but for T-cell receptor (TCR) based cell therapies targeting solid tumors.

An oncology biotech similar to an early BioNTech, focused on pioneering T-cell receptor (TCR) immunotherapies for cancer.

• ACTengine® Therapies: Patient-specific T-cell receptor (TCR) engineered T-cell therapies designed to target and kill cancer cells.
• TCER® Molecules: Bispecific T-cell engaging molecules developed to redirect a patient's own T-cells to tumor cells.

Immatics (IMTX) is a clinical-stage biopharmaceutical company focused on developing T-cell receptor (TCR) based immunotherapies for cancer. As such, it primarily sells its research, development, and intellectual property in the form of strategic collaborations and licensing agreements to larger pharmaceutical and biotechnology companies, rather than directly to individuals.

Its major customers and collaboration partners, which provide significant upfront payments, milestone payments, and potential royalties for the development of therapeutic candidates, include:

• Bristol-Myers Squibb (Symbol: BMY)
• Genmab (Symbol: GMAB)

Gilead Sciences (GILD)

Harpreet Singh, Ph.D. Chief Executive Officer

Harpreet Singh co-founded Immatics in 2000 and Immatics US in 2015. He has served as Chief Executive Officer of Immatics since 2019. Dr. Singh has played a leadership role in the company's inception, strategic and business development, public listing at NASDAQ in 2020, and in raising over $850 million of venture capital, IPO, and public follow-on proceeds. He was awarded "Private Company CEO of the Year" in 2018.

Venkat Ramanan, Ph.D. Chief Financial Officer

Venkat Ramanan was appointed Chief Financial Officer of Immatics in October 2025. He brings over 25 years of experience in finance, strategy, and operations within the biopharmaceutical industry. Prior to joining Immatics, he served as CFO of Anthos Therapeutics, a Novartis company, and was CFO of Turnstone Biologics, where he led the company through its IPO. Anthos Therapeutics was acquired by Novartis in April 2025. He also held senior finance and business leadership roles at Seagen, Gilead Sciences, and Amgen.

Carsten Reinhardt, M.D., Ph.D. Chief Development Officer

Carsten Reinhardt has served as Chief Development Officer of Immatics since 2020, and as Chief Medical Officer from 2009 to 2020. He leads Immatics' Product Development Strategy and TCR Bispecifics platform. Before joining Immatics, Dr. Reinhardt was Chief Medical Officer of Micromet Inc., where he was instrumental in the company becoming public on Nasdaq and in various deals and transactions that led to its acquisition by Amgen. He also served as International Medical Leader at Hoffmann-La Roche and Head of Clinical Development of Fresenius Biotech GmbH.

Cedrik Britten, M.D. Chief Medical Officer

Cedrik Britten was appointed Chief Medical Officer of Immatics in June 2020. He has more than ten years of experience in clinical and preclinical research and immuno-oncology drug development. Previously, he was Vice President and Head of the Oncology Cell Therapy Research Unit at GlaxoSmithKline and held various senior positions at BioNTech, including Vice President for R&D.

Toni Weinschenk, Ph.D. Chief Innovation Officer

Toni Weinschenk co-founded Immatics in 2000 and is currently Chief Innovation Officer. He oversees Immatics' target discovery, bioinformatics, companion diagnostics activities, and intellectual property. Dr. Weinschenk is the inventor of Immatics' proprietary XPRESIDENT technology platform, which enables the discovery and validation of innovative targets for immuno-oncology.

The most significant clear emerging threat to Immatics (IMTX) is the rapid advancement and potential clinical success of allogeneic (off-the-shelf) T-cell therapies by competing biotechnology and pharmaceutical companies. While Immatics has its own allogeneic programs (ACTallo®), a number of other companies are heavily invested in developing readily available, universally applicable T-cell therapies that do not require patient-specific cell collection and manufacturing, a hallmark of autologous therapies (which constitute Immatics' lead ACTengine® programs).

Should competitors successfully bring to market allogeneic TCR-T or even advanced allogeneic CAR-T therapies with compelling efficacy, superior safety profiles, and streamlined manufacturing capabilities, these products could offer substantial advantages in terms of scalability, cost-effectiveness, and immediate availability compared to Immatics' current autologous cell therapy pipeline. This would represent a disruptive shift in the therapeutic landscape for solid tumors, akin to how streaming services offered a more convenient and scalable model than traditional physical media rental businesses.

Immatics' primary product with a clearly defined addressable market is IMA203 (anzu-cel), their lead TCR-T cell therapy targeting PRAME.

The addressable market for IMA203 (anzu-cel) in its initial target indications is as follows:

• Approximately 7,300 patients for PRAME/HLA-A*02:01-positive second-line (2L) unresectable or metastatic cutaneous melanoma.
• Approximately 1,300 patients for uveal melanoma.

This totals an addressable patient population of approximately 9,000 patients for these first target indications. The market size is for the U.S. and EU5 (Germany, France, Italy, Spain, and the UK).

Immatics also has other product candidates in its pipeline, including IMA203CD8, IMA401, and IMA402, which target various solid tumors and PRAME-positive cancers. However, specific addressable market sizes in terms of patient numbers or monetary value for these other products are not explicitly quantified in the available information.

Immatics (IMTX), a clinical-stage biopharmaceutical company focused on T cell-redirecting cancer immunotherapies, is expected to drive future revenue growth over the next 2-3 years primarily through the advancement and potential commercialization of its pipeline candidates and the establishment of new or expanded collaboration agreements.

Here are the key drivers:

1. Advancement and Potential Commercialization of ACTengine® IMA203 (PRAME) for Advanced Melanoma: Immatics' most advanced program, ACTengine® IMA203, is progressing to a Phase 3 trial for advanced melanoma. The company has reported positive clinical data for IMA203 and anticipates a Biologics License Application (BLA) submission in the first half of 2027 and a potential launch in the second half of 2027. This represents a significant new product launch that would directly contribute to revenue.
2. Progression and Potential Future Commercialization of TCER® IMA402 (PRAME): Immatics is advancing its TCER® IMA402 program, which targets PRAME. Initial Phase 1 clinical data for IMA402 has demonstrated a favorable tolerability profile and early signs of anti-tumor activity. Continued positive clinical development could lead to future collaboration agreements or eventual market entry.
3. Clinical Development of ACTengine® IMA203CD8 (PRAME) and TCER® IMA401 (MAGEA4/8): Further positive clinical data and advancement of other pipeline candidates, such as the next-generation ACTengine® IMA203CD8 and TCER® IMA401, could generate future revenue. IMA203CD8 has shown enhanced pharmacology and potency, while IMA401 has demonstrated initial clinical anti-tumor activity in multiple tumor types. Successful progression through trials for these assets increases their value for potential partnerships or eventual commercialization.
4. New and Expanded Collaboration Agreements: As a clinical-stage company, a substantial portion of Immatics' revenue has historically come from collaboration agreements, including milestone payments and research funding. Continued positive clinical results from its pipeline programs could attract new strategic partners or lead to the expansion of existing collaborations, thereby generating additional revenue streams.

Share Issuance

• Immatics went public in July 2020 through a business combination with Arya Sciences Acquisition Corp., a special purpose acquisition company (SPAC), which brought in approximately $253 million in gross proceeds, comprising $149 million from Arya's trust account and $104 million from a private investment in public equity (PIPE). This transaction involved the issuance of 17,968,750 ordinary shares and 7,187,500 public warrants to Arya shareholders.
• In October 2022, Immatics completed an underwritten public offering of 10,905,000 ordinary shares at a price of $10.09 per share, generating approximately $110 million in gross proceeds.
• In October 2024, Immatics priced a public offering of 16,250,000 ordinary shares at $9.25 per share, anticipating gross proceeds of approximately $150 million.

Inbound Investments

• As part of its 2020 Nasdaq listing, Immatics received approximately $149 million from Arya's trust account and an additional $104 million from a PIPE led by Perceptive Advisors and other institutional investors.
• Immatics has established strategic collaboration agreements with major pharmaceutical companies, including Bristol Myers Squibb, Moderna, GlaxoSmithKline, and Amgen, which include upfront payments and potential milestone payments. For example, a 2019 agreement with Celgene (now part of Bristol Myers Squibb) was valued at up to $1.5 billion and included a $75 million upfront payment.
• In July 2023, Immatics raised $35 million in a Post IPO funding round, with Bristol-Myers Squibb identified as one of the investors.